Updates Information About Extent Of Serious Developmental Disorders Such As Autism Spectrum Disorders (ASD) As Well As Congenital Malformations And Birth Defects Like Spina Bifida
SUMMARY: On January 22, 2015 the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) issued a Drug Safety Alert, “Medicines related to valproate: risk of abnormal pregnancy outcomes”, which has to do with these drugs:
- Depakote, Depakote CP, and Depakote ER (divalproex sodium)
- Depacon (valproate sodium)
- Depakene (valproic acid)
All of these drugs are manufactured and sold by the drug company AbbVie Inc. (formerly Abbott).
The subtitle of this MHRA warning conveys the bottom-line message plain and clear:
Children exposed in utero to valproate are at a high risk of serious developmental disorders (in up to 30-40% of cases) and/or congenital malformations (in approximately 10% of cases).
We will watch to see if there are any further Depakote / Depacon / Depakene label changes regarding autism and/or birth defects here in the US like those that are forthcoming in the UK, according the January 2015 Drug Safety Update regarding these valproate drugs.
For more about the safety issues concerning these drugs, see our Depakote / Depakene / Depacon drug information page.[Read this article in full at original source]
Strictly Confidential, No Obligation.